Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Amitiza
Lubiprostone is a bicyclic fatty acid derivative that acts as a chloride channel activator, specifically targeting ClC-2 channels in the gastrointestinal tract. It is used to treat chronic idiopathic constipation (CIC) in adults, opioid-induced constipation (OIC) in adults with chronic non-cancer pain, and irritable bowel syndrome with constipation (IBS-C) in women 18 years and older. Lubiprostone increases intestinal fluid secretion, which softens the stool and accelerates gastrointestinal transit time, facilitating bowel movements.
For the treatment of chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation.
Outcome:
Reduced efficacy of lubiprostone
Mechanism:
Anticholinergics decrease intestinal motility
Outcome:
No clinically significant interactions expected
Mechanism:
Unknown
Outcome:
Potential increased risk of nausea
Mechanism:
Unknown
Most likely new formulation: Modified-release formulation for once-daily dosing (2025, 60% confidence)
Based on current usage trends and clinical trial data, there is a low likelihood (<10%) of any major regulatory changes for lubiprostone in the next 2 years.
Chloride Channel Activator, Laxative
Bicyclic Fatty Acid Derivative